Trial reportHaematologica2019
Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.
Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.British journal of haematology · 2021Trial
- PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.Blood · 2019Trial
- Article
- Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment.HemaSphere · 2022Article
- Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review.Frontiers in oncology · 2022Review
- Article
- Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Review
- Advances in targeted therapy for malignant lymphoma.Signal transduction and targeted therapy · 2020Review
- Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth.Frontiers in immunology · 2020Review
- Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.